Open AccessOpportunistic infections complicating immunotherapy for non‐small cell lung cancer
Author(s) -
Liu Ziwei,
Liu Tao,
Zhang Xiaotong,
Si Xiaoyan,
Wang Hanping,
Zhang Jingjia,
Huang Hui,
Sun Xuefeng,
Wang Jinglan,
Wang Mengzhao,
Zhang Li
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13422
Subject(s) - medicine , immunotherapy , bronchoalveolar lavage , lung cancer , bronchoscopy , nivolumab , adverse effect , opportunistic infection , oncology , cancer , intensive care medicine , lung , immunology , viral disease , virus
Immunotherapy has produced durable responses in numerous advanced and metastatic cancers, especially advanced non‐small cell lung carcinoma (NSCLC). However, opportunistic infection has become a major risk for patients who have received immune checkpoint inhibitors (ICIs). Early diagnosis of infection is difficult due to an acute disease course and heterogeneity in clinical manifestation. We retrospectively analyzed four cases with NSCLC who received ICIs and developed opportunistic infections. Two of our cases received antecedent glucocorticoids to treat immune‐related adverse events (irAEs), whereas immunosuppressive agents were not used beforehand in the other cases. We highlight that opportunistic infections complicating immunotherapy can be severe and even fatal. When patients deteriorate after initial remission from irAEs by glucocorticoids, infections should be thoroughly investigated and carefully distinguished from an irAE flare. Bronchoscopy and bronchoalveolar lavage (BAL) are essential. In patients where limited results from traditional microbiological tests have been obtained, next‐generation sequencing (NGS) of BAL fluid is beneficial in guiding a precise antimicrobial treatment. An antipneumocystis prophylaxis may also be considered in selected patients.